Log in

Mesoblast News Headlines (NASDAQ:MESO)

$6.11
-0.01 (-0.16 %)
(As of 11/14/2019 02:28 AM ET)
Today's Range
$6.08
Now: $6.11
$6.19
50-Day Range
$4.85
MA: $6.19
$7.03
52-Week Range
$3.35
Now: $6.11
$7.59
Volume6,000 shs
Average Volume46,821 shs
Market Capitalization$609.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77

Headlines

Mesoblast (NASDAQ MESO) News Headlines

Source:
DateHeadline
Global Stem Cells Market 2019 by Excellent Revenue Growth by 2025 | MRE Research ReportGlobal Stem Cells Market 2019 by Excellent Revenue Growth by 2025 | MRE Research Report
www.marketwatch.com - November 13 at 12:06 PM
Stem Cells Market 2019 by Excellent Revenue Growth by 2025 | MRE Research ReportStem Cells Market 2019 by Excellent Revenue Growth by 2025 | MRE Research Report
www.marketwatch.com - November 12 at 3:29 PM
Mesoblast limited (NASDAQ:MESO) to Post FY2020 Earnings of ($0.78) Per Share, Cantor Fitzgerald ForecastsMesoblast limited (NASDAQ:MESO) to Post FY2020 Earnings of ($0.78) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - October 25 at 7:45 AM
Mesoblasts (MESO) "Overweight" Rating Reaffirmed at Cantor FitzgeraldMesoblast's (MESO) "Overweight" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - October 22 at 11:02 AM
Cantor Fitzgerald Assumes Mesoblast Limited (MESO) at Overweight - StreetInsider.comCantor Fitzgerald Assumes Mesoblast Limited (MESO) at Overweight - StreetInsider.com
www.streetinsider.com - October 22 at 8:01 AM
Mesoblast limited (NASDAQ:MESO) Given Average Recommendation of "Buy" by BrokeragesMesoblast limited (NASDAQ:MESO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 22 at 5:46 AM
The Daily Biotech Pulse: FDA Panel Backs Shionogis Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO - Yahoo FinanceThe Daily Biotech Pulse: FDA Panel Backs Shionogi's Antibiotic, Hepion Surges On Data Publication, Innate Pharma IPO - Yahoo Finance
finance.yahoo.com - October 17 at 1:45 PM
BRIEF-Mesoblast Says Co & Lonza Enter Agreement For Commercial Manufacture Of Cos Allogeneic Cell Therapy - ReutersBRIEF-Mesoblast Says Co & Lonza Enter Agreement For Commercial Manufacture Of Co's Allogeneic Cell Therapy - Reuters
www.reuters.com - October 17 at 8:45 AM
Why Challenger, IOOF, Mesoblast, & Nearmap shares climbed higher today - Yahoo FinanceWhy Challenger, IOOF, Mesoblast, & Nearmap shares climbed higher today - Yahoo Finance
au.finance.yahoo.com - October 17 at 8:45 AM
Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblasts Potential First United States Allogeneic Cell Therapy - GlobeNewswireMesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast's Potential First United States Allogeneic Cell Therapy - GlobeNewswire
www.globenewswire.com - October 17 at 8:45 AM
Mesoblast closes A$75M capital raising - Seeking AlphaMesoblast closes A$75M capital raising - Seeking Alpha
seekingalpha.com - October 3 at 3:34 PM
Mesoblast Completes Successful Institutional Capital Raising of A$75 Million - Yahoo FinanceMesoblast Completes Successful Institutional Capital Raising of A$75 Million - Yahoo Finance
finance.yahoo.com - October 3 at 3:34 PM
Stem Cells Market 2019 Analysis and Depth Research Recent Trends, Size, Share, Growth Factors and Forecast to 2024Stem Cells Market 2019 Analysis and Depth Research Recent Trends, Size, Share, Growth Factors and Forecast to 2024
www.marketwatch.com - October 3 at 9:30 AM
Mesoblast Completes Successful Institutional Capital Raising of A$75 MillionMesoblast Completes Successful Institutional Capital Raising of A$75 Million
finance.yahoo.com - October 3 at 9:30 AM
Why Mesoblast, NAB, Nearmap, & Santos shares crashed lower today - Yahoo FinanceWhy Mesoblast, NAB, Nearmap, & Santos shares crashed lower today - Yahoo Finance
au.finance.yahoo.com - October 3 at 3:57 AM
Why the Mesoblast share price crashed 10% lower today - Yahoo FinanceWhy the Mesoblast share price crashed 10% lower today - Yahoo Finance
au.finance.yahoo.com - October 2 at 10:13 PM
Mesoblast shares halted as it asks investors to tip in another $75 million - Yahoo FinanceMesoblast shares halted as it asks investors to tip in another $75 million - Yahoo Finance
au.finance.yahoo.com - October 1 at 8:17 AM
Global Diabetic Nephropathy Market research Registering a Strong Growth by 2016-2026Global Diabetic Nephropathy Market research Registering a Strong Growth by 2016-2026
www.marketwatch.com - September 27 at 9:31 PM
Will Mesoblast Continue to Surge Higher? - Yahoo FinanceWill Mesoblast Continue to Surge Higher? - Yahoo Finance
finance.yahoo.com - September 25 at 12:13 PM
Will Mesoblast Continue to Surge Higher?Will Mesoblast Continue to Surge Higher?
finance.yahoo.com - September 25 at 12:13 PM
What’s Next in Pain Management in the Wake of the Opioid Crisis - BarronsWhat’s Next in Pain Management in the Wake of the Opioid Crisis - Barron's
www.barrons.com - September 23 at 9:45 AM
The Opioid Crisis Has Upended Pain Management. What’s Next for the Industry.The Opioid Crisis Has Upended Pain Management. What’s Next for the Industry.
finance.yahoo.com - September 23 at 9:45 AM
3 Biotech Stocks That Soared Last Week - The Motley Fool3 Biotech Stocks That Soared Last Week - The Motley Fool
www.fool.com - September 17 at 5:09 AM
Gruenthal, Mesoblast (MESO) Enter Strategic Partnership for Europe and Latin America for Cell Therapy for Treatment of Chronic Low Back Pain - StreetInsider.comGruenthal, Mesoblast (MESO) Enter Strategic Partnership for Europe and Latin America for Cell Therapy for Treatment of Chronic Low Back Pain - StreetInsider.com
www.streetinsider.com - September 11 at 12:35 PM
The Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris - Yahoo FinanceThe Daily Biotech Pulse: Translate Bio Halts mRNA Therapy Trial, Roche Multiple Sclerosis Biomarker Data, D-Day For Xeris - Yahoo Finance
finance.yahoo.com - September 10 at 8:48 PM
Mesoblast (MESO) will provide corporate update during analyst call today - StreetInsider.comMesoblast (MESO) will provide corporate update during analyst call today - StreetInsider.com
www.streetinsider.com - September 10 at 3:48 PM
Mesoblast up 14% premarket on Grünenthal partnership - Seeking AlphaMesoblast up 14% premarket on Grünenthal partnership - Seeking Alpha
seekingalpha.com - September 10 at 3:48 PM
Grünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain - Yahoo FinanceGrünenthal and Mesoblast Enter Strategic Partnership for Europe and Latin America to Develop and Commercialise Innovative Cell Therapy for the Treatment of Chronic Low Back Pain - Yahoo Finance
finance.yahoo.com - September 10 at 3:48 PM
Mesoblast Corporate Update: Analyst Call Australian Stock Exchange:MSB.AX - GlobeNewswireMesoblast Corporate Update: Analyst Call Australian Stock Exchange:MSB.AX - GlobeNewswire
www.globenewswire.com - September 10 at 3:48 PM
Form 6-K MESOBLAST LTD For: Aug 31 - StreetInsider.comForm 6-K MESOBLAST LTD For: Aug 31 - StreetInsider.com
www.streetinsider.com - September 7 at 10:14 AM
Mesoblast Limited 2019 Q4 - Results - Earnings Call SlidesMesoblast Limited 2019 Q4 - Results - Earnings Call Slides
seekingalpha.com - August 31 at 3:15 PM
Mesoblast Reports 2019 Full Year Results Australian Stock Exchange:MSB.AX - GlobeNewswireMesoblast Reports 2019 Full Year Results Australian Stock Exchange:MSB.AX - GlobeNewswire
www.globenewswire.com - August 30 at 3:19 PM
Edited Transcript of MSB.AX earnings conference call or presentation 29-Aug-19 10:00pm GMT - Yahoo FinanceEdited Transcript of MSB.AX earnings conference call or presentation 29-Aug-19 10:00pm GMT - Yahoo Finance
finance.yahoo.com - August 30 at 11:39 AM
Mesoblasts (MESO) CEO Silviu Itescu on Q4 2019 Results - Earnings Call Transcript - Seeking AlphaMesoblast's (MESO) CEO Silviu Itescu on Q4 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 30 at 11:39 AM
Mesoblast Reports 2019 Full Year Results - Yahoo FinanceMesoblast Reports 2019 Full Year Results - Yahoo Finance
finance.yahoo.com - August 29 at 8:08 PM
After-Hours Earnings Report for August 29, 2019 : WDAY, ULTA, COO, MRVL, YEXT, AMBA, MESO, AOBC - NasdaqAfter-Hours Earnings Report for August 29, 2019 : WDAY, ULTA, COO, MRVL, YEXT, AMBA, MESO, AOBC - Nasdaq
www.nasdaq.com - August 29 at 3:06 PM
Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019 - GlobeNewswireMesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019 - GlobeNewswire
www.globenewswire.com - August 28 at 11:51 AM
Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019 - Yahoo FinanceMesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019 - Yahoo Finance
finance.yahoo.com - August 27 at 8:15 PM
Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019Mesoblast to Host Analyst Call on 2019 Financial Results for Year and Fourth Quarter Ended June 30, 2019
finance.yahoo.com - August 27 at 8:15 PM
Form 6-K MESOBLAST LTD For: Aug 19 - StreetInsider.comForm 6-K MESOBLAST LTD For: Aug 19 - StreetInsider.com
www.streetinsider.com - August 19 at 3:13 PM
Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial - GlobeNewswireRemestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial - GlobeNewswire
globenewswire.com - August 14 at 8:36 AM
Remestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated TrialRemestemcel-L to be Evaluated as Treatment for Chronic Graft Versus Host Disease in Planned Investigator-Initiated Trial
finance.yahoo.com - August 14 at 8:36 AM
Global Stem Cell Market Value is Expected to Reach $28.49 Billion by 2022 - A Report by TBRC - Yahoo FinanceGlobal Stem Cell Market Value is Expected to Reach $28.49 Billion by 2022 - A Report by TBRC - Yahoo Finance
finance.yahoo.com - August 13 at 3:09 PM
Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer - GlobeNewswireMesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer - GlobeNewswire
globenewswire.com - August 12 at 11:29 PM
Mesoblast share price edges higher on quarterly updateMesoblast share price edges higher on quarterly update
www.msn.com - August 2 at 8:11 PM
Form 6-K MESOBLAST LTD For: Jul 31 - StreetInsider.comForm 6-K MESOBLAST LTD For: Jul 31 - StreetInsider.com
www.streetinsider.com - August 2 at 3:07 PM
Mesoblast share price edges higher on quarterly update - Motley Fool AustraliaMesoblast share price edges higher on quarterly update - Motley Fool Australia
www.fool.com.au - August 1 at 7:28 AM
Mesoblast Quarterly Cash Flow Report Australian Stock Exchange:MSB.AX - GlobeNewswireMesoblast Quarterly Cash Flow Report Australian Stock Exchange:MSB.AX - GlobeNewswire
globenewswire.com - July 31 at 12:00 PM
Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market?Does The Mesoblast Limited (ASX:MSB) Share Price Tend To Follow The Market?
finance.yahoo.com - July 28 at 5:09 AM
Circulation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure - GlobeNewswireCirculation Research Special Article Highlights Potential Of Mesoblast Cell Therapy In Treatment Of Advanced Heart Failure - GlobeNewswire
globenewswire.com - July 25 at 1:30 PM
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Featured Article: Momentum Investing

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel